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ProteinproﬁlingusingSELDI-TOF-MShasgainedoverthepastfewyearsanincreasinginterestintheﬁeldofbiomarkerdiscovery.
The technology presents great potential if some parameters, such as sample handling, SELDI settings, and data analysis, are strictly
controlled. Practical considerations to set up a robust and sensitive strategy for biomarker discovery are presented. This paper also
reviews biological ﬂuids generally available including a description of their peculiar properties and the preanalytical challenges
inherent to sample collection and storage. Finally, some new insights for biomarker identiﬁcation and validation challenges are
provided.
1.Introduction
The objective of biomarker discovery is to identify speciﬁc
protein markers susceptible to improve early diagnosis
survey therapeutic outcomes and facilitate the development
of novel drug candidates [1, 2]. The methodology relies on
diﬀerential protein expression proﬁling. The fundamental
approach is based on the assumption that the pathology
of concern will aﬀect some physiological processes causing
changes in the protein expression levels. Proteins generating
similar signals in both sample groups are ignored while sig-
niﬁcantly up- and downregulated proteins become potential
biomarkers. Diﬀerential expression proﬁling requires both
a sensitive technology to discern any tiny diﬀerences and
a high-throughput system in order to process large series
of samples required to reach statistical signiﬁcance. Protein
diﬀerential display techniques such as two-dimensional gel
electrophoresis (2-DE), one- or two-dimensional liquid
chromatographic (LC-MS), or surface-enhanced laser des-
orption/ionization time of ﬂight mass spectrometry (SELDI-
TOF-MS) are regarded as the most powerful tools for
establishing ﬁngerprint proﬁles [3–6].
Many reports regarding the application of the SELDI-
TOF-MS technology have been published since its introduc-
tionin1993[7]anditsﬁrstusefordiseasedetection[8].One
of the key features of SELDI-TOF-MS is its ability to provide
rapid protein expression proﬁles from a variety of biological
samples with minimal requirements for puriﬁcation and
separation of proteins prior to mass spectrometry. SELDI-
TOF-MS proﬁling studies revealed that biological ﬂuids
contain many proteins with low molecular weight (<15kDa)
not resolved on conventional 2D gels [6, 9].
A sc a nb es e e ni nF i g u r e1, the SELDI technique
consists in surface arrays involving various chromatographic
models based on both classic chemistries (normal phase,
hydrophobic, cation- and anion-exchange surfaces) and
speciﬁcallyaﬃnity-coatedsurfaces(immobilizedmetalaﬃn-
ity capture : IMAC). After the binding phase of the sample to
these surfaces, the unbound proteins are washed out while
retained molecules are overlaid with an energy-absorbing
matrix. In the ﬁnal step, mass spectra are recorded using a
laser for the ionization and a TOF mass spectrometer for its
resolving power.2 Journal of Biomedicine and Biotechnology
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Figure 1: Eﬀects of diﬀerent ProteinChip array surfaces and wash conditions. The combination of ProteinChip array surface types and wash
conditions maximize the potential for protein biomarker discovery.
Recent interest in the ﬁeld has yielded a large number of
candidate biomarkers in various diseases [10–35]. However,
the small size and poor design of some studies drove
validation of these biomarkers quite challenging [36–41].
In the context of clinical proteomic using SELDI-TOF-
MS, many recent reviews discussed newly identiﬁed disease
biomarkers [13, 21, 22, 24, 27, 30, 35, 42–44]. The present
review focuses on technical challenges encountered with
the SELDI-TOF-MS technology taking into account new
insights coming from the last three years. Critical steps
that should be undertaken to avoid any bias, to maximize
reproducibilityanddetectionsensitivity,withtheﬁnalaimto
ﬁnd relevant, speciﬁc, and robust biomarkers are addressed
[45, 46]. For prospective studies, current knowledge on
the diﬀerent biological ﬂuid sources available for SELDI-
TOF-MSexperimentsisdescribedpresentingtheirrespective
advantages and limitations.
2. Study Design
A successful biomarker research program starts with a
careful study design and the preparation of a detailed
protocol. Many manuscripts report encountered problems,
emphasizing the importance of Standard Operating Pro-
cedures (SOPs), clinical protocols, instrument tuning, and
stabilization [37–40, 47–63]. Only critical points will be
discussed in this review.
In the early phase of biomarker discovery, the clinical
questionaddressedhastobedeﬁnedinthedisease(s)context
collecting adequate control samples. Indeed, it can be criti-
cizedthatinmanypublishedstudies,patientswerecompared
to healthy subjects rather than to patients presenting similar
diseases or clinical signs.
Experimental workﬂow and technologies have to be
s e l e c t e dw i t hg r e a tc a r e .T h ea v o i d a n c eo fb i a si sn o t
trivial and must be addressed throughout the whole study,
from its design to the data analysis and interpretation (cf.
Figure 2). Current proteomics and genomics technologies
are extremely sensitive and can detect very small changes
in expression levels. Some of these changes may arise from
biological diﬀerences related to disease or pharmacological
treatment. They could also result from the heterogeneity
of the patient panels tested across multiples sites, the
inherent biological complexity, and the diversity of sampleJournal of Biomedicine and Biotechnology 3
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Figure 2: Experimental variables that can aﬀect proteomics data. Most of the steps shown are involved in all proteomics workﬂows, but
SELDI technology performs many of them on a single platform.
types. Small diﬀerences in sample collection, processing,
and analytical techniques could have some impact on the
outcomes of the study. As a consequence, clinical data may
be site-, study-, population-, or sample-dependent, without
any actual clinical relevance [53, 62, 64–66]. The key factor
for maximizing reproducibility in biomarker research is to
identify and minimize all potential sources of preanalytical
and analytical bias [53, 55]( T a b l e1). Adherence to strict
guidelines and SOPs is critical to reach the highest operating
standards for data quality and reproducibility [37, 38,
47, 50, 51, 53, 55, 62, 63, 67]. SOPs also facilitate the
validation of biomarkers by other groups using diﬀerent sets
of samples.
3. Sample HandlingandPreparation
Besides the instrumentation and the methodologies
related to chromatography-mass spectrometry analysis,
the nature, quality, and number of clinical samples to
process are key elements to be considered for any proteomic
approaches.
3.1. Selection of Body Fluid. I no r d e rt op r o v i d ep o s i t i v e
answer to any precise clinical question, the investigator
has to make a choice among the most relevant biolog-
ical target samples (body ﬂuid, tissue, etc.). Many cri-
teria must be considered at this level, that is, availabil-
ity, easiness of collection, stability, composition, proximity
with disease location, patient discomfort, ethics, and so
forth.
For biomarker discovery using SELDI-TOF-MS, a great
variety of biological sample types can be used; major
applications concern bioﬂuids (plasma, serum, urine, saliva,
cerebrospinal liquid, bronchoalveolar wash out, nipple aspi-
rate ﬂuid, tears, amniotic ﬂuid) [1, 10–14, 18, 19, 21, 22,
24, 28, 42, 48, 49, 68–77], and tissues or cell extracts [78,
79]. Among them, serum, plasma, urine, and saliva are the
most popular. Many variables related to collection, storage,
and conditions for sample preparations have to be carefully
considered. These parameters have been commented in
literature according to the nature of the bioﬂuids [48, 49,
54, 57, 61, 67, 73, 74, 80–84]. In this section of the review,
consensus opinions derived from these recent studies are
provided. Advantages and drawbacks of the most popular4 Journal of Biomedicine and Biotechnology
Table 1: Factors that impact preanalytical and analytical bias.
Preanalytical bias
Patients information
Age, gender, ethnicity
Disease subtype and/or severity
Medical background
Health background
Smoking status, alcohol intake, diet, other risk factors
Drug treatments
Patient position (seated/standing/lying), daily moment of collection
Type of control (healthy or disease)
Location of sample collection (single or multisite)
Study inclusion and exclusion criteria
Sample characteristics
Number of individuals
Type (blood, serum, plasma, urine, cerebrospinal ﬂuid, cell lysate, etc.)
Source (banked or prospectively collected)
Sample-handling procedures
Collection protocols (initial processing, procedure, timing, type of antico-
agulant, type of tubes, number of sites, etc.)
Storage procedures (time, aliquoting, storage materials, temperature,
freeze-thaw cycles, etc.)
Analytical bias
Sample-Processing procedures
Fractionation and depletion methods
Processing steps (denaturation, buﬀer components, delipidation, etc.)
Liquid handling methods (automated or manual, technique, equipment,
etc.)
Experimental protocols
Array types
Sample pH and dilution factor
Quantity of sample loading and position on arrays
Sample binding, washing and drying procedures
Matrix addition (type and method)
Instruments settings
Number of instruments, locations
Environmental factors (temperature, humidity percentage)
Data analysis methods
Spectrumprocessing(baselinesubtraction,normalization,alignment,noise
reduction, etc.)
Peak labelling
Feature selection, statistical analysis
Classiﬁcation approaches
ﬂuids are presented in Table 2 as well as formulated
recommendations. When reviewing a series of studies [47–
49, 51, 54, 57, 58, 60, 61, 67, 68, 73, 81–83, 85] general
guidelines can be forwarded. Optimal serum clotting arises
after 60 minutes at room temperature. After clot formation,
samples can be transported or stored on wet ice for 3
hours before centrifugation. Aliquots must be prepared and
stored at −80
◦C. For plasma collection, anticoagulant EDTA
is preferred and its processing should be realized as soon
as possible after sampling, ideally within the ﬁrst hour.
Although storage at low temperature promotes peptides and
proteins stability, one should not recommend storing plasma
samples at 4◦C due to the cold activation of platelets. Prior
any freezing, plasma can be depleted in platelets by using a
ﬁltration step; aliquots are then freezed at −80
◦C.
According to the “HUPO PPP Specimens Committee”
recommendations, plasma appears preferable to serum
because it contains less peptides of degradation and con-
sequently presents less variability [57, 81, 86]. In order to
avoid the presence of platelet related peptides, the authors
also recommend to use platelet-poor plasma obtained by
centrifugation followed by a ﬁltration step. However, the
choice of serum could be justiﬁed when studying diseases
related to coagulation abnormalities. Furthermore, it is often
more available in sample banks for retrospective studies.
A controversial parameter is the addition of protease
inhibitors (PIs) to the samples. Some authors found that the
addition of a PI cocktail induces signiﬁcant diﬀerences in
protein proﬁles when compared to crude samples [58, 83].
Whenever directly introduced during phlebotomy, PI allowsJournal of Biomedicine and Biotechnology 5
Table 2: Advantages and limitations of body ﬂuids particularly useful for biomarker discovery.
Bodyﬂuids Advantages Limitations Recommendations
Serum
(i) established sample
banks often composed of
serum aliquots
(retrospective studies),
(i) presence of various
products derived from
coagulation cascade,
(i) use standardized
collection protocol,
(ii) proteins and peptides
that “survive” to the
clotting procedure exhibit a
stability that can be
exploited in routine clinical
applications.
(ii) biomarker with poor
stability during coagulation
process will not be detected
in serum,
(ii) keep sample during 1
hour at RT to allow clotting
process before
centrifugation,
(iii) possible inﬂuence of
the disease on coagulation
process.
(iii) preserve on ice after
clotting. Aliquoting and
freezing (−80
◦C) cannot be
done immediately.
Plasma
(i) more rapidly processed
than serum (interesting for
emergency diagnosis),
(i) interference with chip
surface (i.e. heparin tube),
(i) use standardized
collection protocol,
(ii) larger ﬁnal volume of
ﬂuid after processing than
with serum,
(ii) sample dilution in
citrate tube,
(ii) carefully choose the
type of anticoagulants
(EDTA tubes are
preferable),
(iii) more stable than
serum due to the inhibition
of coagulation cascade.
(iii) possible interference of
EDTA with protein binding
on IMAC surface,
(iii) use platelet-poor
plasma,
(iv) SELDI-TOF spectra
less rich in peaks number
and intensity than serum.
(iv) centrifuge, aliquot and
freeze (−80
◦C) as soon as
possible. If not possible,
keep at RT to avoid cold
platelet activation.
Dry blood
(i) medical staﬀ not needed
for collection,
(i) elution step to recover
sample from ﬁlter paper.
(i) keep dry specimens at
RT for 3–4 hours in
horizontal position,
(ii) low blood volume
necessary,
(ii) store at −20
◦C.
(iii) easy storage and
transport.
Saliva
(i) easy and noninvasive
sampling,
(i) low volume collected, (i) always collect with the
same method (stimulated
or not) and at the same
moment of the day,
(ii) medical staﬀ not
needed for collection,
(ii) presence of many
proteases and unspeciﬁc
m a t e r i a l ss u c ha sf o o d
residues or
microorganisms,
(ii) centrifuge to remove
insoluble material, aliquot
and freeze at −80
◦C.
(iii) level of certain plasma
proteins are not reﬂected in
saliva.
Urine
(i) easy and noninvasive
collection,
(i) ﬂuctuation of protein
concentration overtime and
according to renal integrity,
(i) use standardized
collection protocol,
(ii) medical staﬀ not
needed for collection,
(ii) presence of salts and
proteins in low
concentration.
(ii) concentrate the
samples,
(iii) obtained in large
volume.
(iii) centrifuge, aliquot and
freeze at −80
◦C,
(iv) normalization with
creatinine content.6 Journal of Biomedicine and Biotechnology
ﬂuid stabilization for at least 2 hours at room temperature
by reducing proteolysis damages. However, PI presents
some additional drawbacks such as the presence of highly
concentrated components in the cocktail which can compete
l a t e ro nf o rp r o t e i na r r a yi n t e r a c t i o n s .
Another important factor to decrease the risk of vari-
ation, bias, and errors is the communication between
researchers and medical staﬀ. One generally considers that
70% of the errors are due to human intervention (mostly
due to communication problems) while only 30% appear
instrumental related errors [87]. The mode of specimen
collection (veni-puncture or arterial puncture), the site of
collection, the position of the patient, or the tourniquet
technique can inﬂuence the concentration of certain blood
constituents [58]. Hemolysis also causes signiﬁcant changes
in blood proteome specimens [67]. It is generally advised to
discard those kinds of samples, but when the disease studied
involves spontaneous hemolysis, this cannot reasonably be
done.
Less commonly used, ﬁlter papers were also described to
collect blood [68]. This mode of collection has the advantage
that only few drops of blood are needed (particularly
interesting for neonatal and repeated screening). Moreover,
it does not require speciﬁc medical support for sampling,
whichcouldbepromisingformultiplecollectsrealizedbythe
patient at home, in the perspective of a treatment follow-up,
for instance. Stability and reproducibility of this collection
mode remain to be studied.
Saliva and urine have more recently presented an interest
in biomarker discovery. Their collection is simple, nonin-
vasive, and cheap and can be easily repeated. However, like
blood specimen, such factors have to be taken into consider-
ation to improve reproducibility of sample collection. Saliva
protein composition varies with circadian rhythm, diet, age,
gender, and physiological status [86]. It is also aﬀected by
the method of sample collection (stimulated versus non-
stimulated saliva production) [60]. Food ingestion increases
the proteolysis activity and then collection before lunch
rather than after is recommended [73]. The addition of
PI can reduce but not completely eliminate the impact
of the proteolysis [60]. It will stabilize, qualitatively and
quantitatively, the saliva proteome for up to 48 hours [73].
Regarding storage conditions, it is preferred to store the
saliva specimens at −80
◦C rather than at −20
◦C where the
preservation of the protein content could not be guaranteed
for more than 1 month. Interestingly, repeated freeze-thaw
cycles (4/5) do not seem to signiﬁcantly alter saliva protein
proﬁle [74].
Urine has the advantage that it can be obtained in large
volume. It is mainly an aqueous solution (95% of water)
of waste electrolytes and metabolites, organic components
(urea, uric acid), and proteins at low concentrations in
healthy individuals (150mg/day). Urine proteome variation
depends mainly on plasma composition due to its role as
blood content regulator and on the integrity of the glomeru-
lar ﬁltration step leading to a large intra and intersubjects
variability.Proteinandsaltconcentrationscanvaryalongthe
day for a same subject (ﬁrst void compared to midstream
urine samples) [80, 88]. Progressive degradation of urine
proteome due to proteolytic activity can be prevented by
PI addition only up to 2 hours of storage [54]. As already
mentioned for blood and saliva, up to 5freeze/thaw cycles
do not signiﬁcantly aﬀect urine proteome proﬁle. Storage at
−80
◦Ci ss t i l lr e q u e s t e d .
Other ﬂuids such cerebrospinal ﬂuid, nipple aspirates,
tears, synovial ﬂuid, bronchoalveolar lavage, follicular, and
amniotic ﬂuids have already been explored by SELDI-TOF-
MS [15, 20, 33, 34, 69, 75, 89, 90] .T h e s eﬂ u i d sa r eg e n e r a l l y
used to study well-localized diseases. Despite the presence
in such ﬂuids of some plasma proteins, their implication to
study systemic diseases is not recommended and diﬃcult to
apply in routine diagnosis due to risk and discomfort related
to collection.
3.2. Sample Processing. One of the most challenging aspects
instudyingbodyﬂuidsproteinproﬁlesremainsthedetection
of the deep proteome [91]. The protein concentration
dynamic range detectable by means of MALDI-TOF or
SELDI-TOF-MS is about 2 orders of magnitude, whereas
the range in blood reaches about 10 orders of magnitude
[91, 92]. As protein binding onto chromatographic surface
depends on its aﬃnity, its concentration, but also on
the surface binding capacity, one can imagine that the
competition between diﬀerent proteins for binding sites is
very complex. A highly abundant protein with low aﬃnity
for the chip surface and a low abundant protein with high
aﬃnity may give similar peak intensities in the ﬁnal SELDI
mass spectrum. Furthermore, protein steric hindrance can
also aﬀect the SELDI proﬁles.
Several fractionation procedures are now available to
decrease the sample protein concentration dynamic range
[85, 93–102].
A major inconvenience for sample fractionation is the
resulting low sample throughput capacity, due to a signiﬁ-
cant increase of the duration of analysis and to a risk of poor
reproducibility aﬀecting data treatment. Use of automatized
technologies can improve the reproducibility and decrease
the total analysis time. Additionally the same proteins can be
presented in diﬀerent fractions challenging the comparison
of their abundance between samples.
Several methods have been proposed for fractionation
such as centrifugal ultraﬁltration, precipitation by organic
solvents, electrophoresis, chromatography (on-column or
on-magnetic beads), or subcellular localization. The choice
willbemadebasedonthenatureofthesampletobeanalysed
and the protein properties (molecular weight, localization,
abundance, etc.). All these sample preparation methods have
already been discussed by other reviewers [85, 94, 101,
103, 104]. Recently, with the growing interest in studying
posttranslational modiﬁcations new methodologies set up to
isolate rare amino acid-containing peptides (cys, met, trp,
his) or PTM peptides (phosphopeptides, glycopeptides) have
been developed [25]. One of the most widely used approach
forhighlyabundantproteinsremovalinserumandplasmais
their depletion using antibodies. Despite the depletion of the
ninemostabundantproteinsfromserumorplasmasamples,
overallpublishedresultswerequitedisappointing[105].ThisJournal of Biomedicine and Biotechnology 7
sensitivity problem is most probably inherent to the too
low concentration of the peptidome constituents. Moreover,
some of the abundant proteins act as carrier explaining the
codepletion of almost 3000 species (peptides and proteins)
as observed by several groups [106].
A new fractionation approach has been recently devel-
opedbyRighettiandBoschetti[107].Itimpliedasolid-phase
combinatorial library of hexapeptides on which millions of
copies of a unique ligand are graft on a bead. This technique,
enablingthedilutionofabundantproteinbyrapidsaturation
of its ligand, concentrates components of the deep proteome
which could not reach saturation. This method presents the
advantage to reduce the dynamic range between the most
and less abundant proteins and peptides. It has also been
showed that despite compression of the dynamic range, this
technology used for diﬀerential studies was only applicable
for proteins or peptides which do not reach saturation
(low and medium abundance proteins) [107]. Many stud-
ies conducted on diﬀerent types of samples report good
reproducibility and important gain in the number of low
abundantspecies bycomparison withanalysesperformedon
corresponding crude samples [96, 98, 99, 108–111], which
make this approach very promising to investigate the deep
proteome.
4.SELDISettings
In order to highlight candidate protein biomarkers, several
chromatographic surfaces must be screened. The choice of
the protein chip array chemistry and the nature of the
matrix depend on whether the application requires general
proﬁling or requires a speciﬁc protein assay. Diﬀerent array
types and binding conditions may generate complementary
protein proﬁles for the same sample [7]. The use of relevant
quality controls (QCs) is highly recommended and even
mandatory in such applications [37–40, 47–63]. QCs should
be well-characterized pools of samples processed alongside
the experimental samples in order to monitor instrument
performances, optimize mass spectrometry settings (laser
energy, etc.), compare target protein proﬁles to those of
historical reference samples, and to calculate coeﬃcient of
variation for peak intensities as a measure of reproducibility.
It is important to point that the resolution and mass
accuracy provided by this kind of instrument are rather
low compared to high-resolution mass spectrometers (i.e.,
Q-TOF, FT-MS, etc.). Using SELDI-TOF-MS, one could
not expect to accurately determined m/z values or peak
intensities on complex mixtures. Indeed, low resolution
causes peaks overlap making abundance and mass assign-
ment diﬃcult. This means that only large diﬀerences in peak
intensities are to be considered and that peaks of interest
have to be identiﬁed with more accurate mass spectrometers.
Beside those instrumental weaknesses, on the contrary to
other mass spectrometers, SELDI-TOF-MS can be used for
high throughput analysis.
During SELDI settings, numerous sources of spectra
variability have to be taken into account.
Several events, such as matrix crystallization, ion sup-
pression, and in-source decay occurring during mass spectra
acquisition strongly inﬂuence the peak intensities. These are
commented in more details below.
4.1. Matrix Crystallization. Diﬀerences in reagents, handling
of material, room temperature, and level of humidity may
all inﬂuence the (co)crystallization step of matrix molecule
with sample causing interday ﬂuctuation. The structure and
nature of the target surface may also aﬀect peak intensities.
These parameters must be highly controlled and standard-
ized for each study protocol. During the crystallization
process, a competition phenomenon can occur between
proteins for crystal inclusion. Easily embedded proteins
will be present at higher concentrations in the matrix and
consequently more eﬃciently desorbed and ionized [47].
To improve sample-to-sample reproducibility of MALDI ion
yield and to increase the precision of peptide quantiﬁcation,
some authors use nitrocellulose in order to improve the
homogeneity of the matrix/analyte crystallization [55, 112,
113]. This operation might also be helpful for SELDI-TOF-
MS measurements.
4.2.IonSuppression. Dependingonsamplecomposition,ion
suppression is another factor that signiﬁcantly contributes to
the variability observed in SELDI-TOF-MS spectra [47, 50,
55]. Indeed, during ionization, analytes compete for protons
that are transferred from matrix molecules. If a protonated
analyte collides with an unprotonated one which has higher
gas-phase basicity, it may pass its proton to the collision
partner. Therefore, the presence of an analyte may reduce
the signal intensity of another. This phenomenon is called
“ion suppression eﬀect.” In a complex protein mixture like
serum, where highly abundant proteins constitute a large
proportion of the total protein content, it is possible that
such peaks override signals from low abundant peptides.
This phenomenon, obviously diﬃcult to prevent in complex
samples, would be more easily controlled on mixtures issued
from fractionation.
4.3. In-Source-Decay. Another source of variations is the
fragmentation of proteins or peptides during mass spec-
trometric process. Fragmentation occurring before the ﬁrst
ﬁeld-free region is called in-source decay (ISD); it is respon-
s i b l ef o rc o n s e c u t i v es e r i e so fi o n s[ 114].
Ekblad et al. showed that ISD generates quite additional
spectral peaks in the spectrum of proteins contained in
serum samples when compared with the data collected for
pure reference proteins [114]. One obviously creates ISD
favourable conditions when optimizing the analytical condi-
tions by maximizing the total peak count, particularly when
using a high laser beam which would increase the thermal
ions energy and consequently the number of collisions
between ions. Hopefully, in-source fragmentation remains
quite limited [114]. Dijkstra et al. developed a method which
deconvolutes the spectrum by appropriately associating
peaks belonging to the same protein [50]. To take beneﬁt8 Journal of Biomedicine and Biotechnology
of this procedure, highly eﬃcient sample fractionation is
recommended.
4.4. Miscellaneous. Other phenomena susceptible to aﬀect
SELDI spectra must be considered. Common mechanisms
accounting for the arising of multiple peaks in mass spectra
include, for example, the formation of salt adducts and
multiply charged ions [50]. Chemical reactions using energy
from the laser may take place between sample protein
molecules, matrix molecules, or molecules from the washing
buﬀers generating intermolecular complexes known as “ions
cluster” [50]. The formation of these complexes increases the
number of spectrum peaks causing artefacts (i.e., satellite
peak at +206 Da corresponds to a SPA adduct). Moreover,
the performance of the SELDI-TOF-MS may change over
time due to possible ﬂuctuation in the laser intensity and/or
detector sensitivity.
All these diﬃculties can be addressed only by substantial
reduction in sample complexity and the application of a
rigorous standardization program of the entire analytical
process. This involves optimized acquisition protocols (i.e.,
avoiding too high laser intensity), a fully operational and
calibrated instrument and the use of suitable QC samples,
similar in nature and complexity to the studied samples.
5.DataAnalysis
5.1. Spectrum Processing. Another important methodologi-
cal source of artefacts is the data analysis of protein proﬁles.
The data preprocessing (calibration, baseline correction,
normalization, peak detection, and peak alignment) repre-
sents a key step for SELDI analysis [115–117].
S p e c t r aa r eg e n e r a l l yn o r m a l i z e di no r d e rt oe q u a l i z eo r
minimizediﬀerentialeﬀectduetoexternalvariation[59,115,
116, 118, 119]. The widely used total ion current (TIC) gives
a clear indication of the impacts of technical variables such
as laser and detector performances, matrix application, and
sample amounts. TIC normalisation relies on the assump-
tion that the technical parameters are mostly responsible
for the largest diﬀerences observed between samples. But
Cairns et al. showed that TIC may also potentially remove
some pertinent biological information [115]. They suggest
toexaminewhethernormalisationfactorsvarysystematically
between study groups and they recommend to specify the
applied methodology (local or global normalisation, matrix
signal excluded or not). The ideal normalisation procedure
would be to resort to some internal spiking method.
5.2. Classiﬁcation Approaches. One important aspect in
SELDI-TOF-MS data analysis is to avoid false discovery of
protein peaks, for which the discriminative power results
from random variation. A general criticism concerns the
use of inadequate algorithms for data analysis and the
problem issued from over-adjustment in combination of
high-dimensional data with a low number of cases. Those
artefacts could be prevented by analysing a suﬃcient number
of samples, by resorting to overﬁtting-resistant algorithms,
by an appropriate validation of the resultant model, and
by using optimal spectra processing techniques (calibration,
exclusion of spectral regions aﬀected by high noise, peak
alignment, and normalization). Two others remarks can be
formulated from literature reports: (1) multiple biomarkers
havegenerallyabetterpredictivevaluethanindividualmark-
ers, and (2) positive-predictive values of peptide patterns are
ofteninsuﬃcienttoberecognizedasearlymarkerswhenthey
concern low-frequency diseases in the population [38, 53].
The most commonly used bioinformatics approaches
are decision tree-based ones and support vector machines
[120, 121]. Authors generally emphasized on the need for
validated model selection using cross validation loop and
permutation testing to develop generalized classiﬁer able to
correctly predict classiﬁcation of new samples [122].
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ClinicalApplication
Identiﬁcation of candidate biomarkers, while not strictly
necessary for diagnostic purpose, can be regarded as
extremely satisfying in helping to data interpretation
and better understanding the disease. As often criticized,
the SELDI-TOF-MS technology does not provide pep-
tide/protein identiﬁcation. In order to succeed in the
identiﬁcation by sequencing (Q-TOF, TOF-TOF, ion-trap,
etc.) or peptide ﬁngerprinting (MALDI-TOF), enrichment
and puriﬁcation of the biomarker of interest is often
needed, which is laborious and time consuming. To solve
in part this weakness, new ProteinChip interface coupled to
tandem mass spectrometer was recently developed allowing
direct sequencing of peptides <6000Da [124]. In all cases,
identiﬁcations must be corroborated using antibody-based
detection (i.e., Western blot or ELISA) or antibody pull-
down with subsequent detection by SELDI-TOF-MS.
It should be noted that the concentration range of widely
used biomarkers in plasma samples is remarkably wide and
diﬀer from the high milligram until low nanogram per
liter range. For example, serum albumin, within a normal
concentration range of 35–50mg/mL, is measured as an
indication of severe liver disease [125] or malnutrition [126],
whereas IL-6 normally varies in a range of 0–5pg/mL,
is measured as a sensitive indicator of inﬂammation or
infection [127].
Untilnow,mostofthemarkersidentiﬁedafteranSELDI-
TOF-MS study could not yet be considered as very speciﬁc of
a given disease but they are rather representative of disease’s
consequences like inﬂammation or immune response. The
most frequently identiﬁed proteins so far are haptoglobulin,
transthyretin, apolipoproteins, serum amyloid, or comple-
ment factors present at μg/mL to mg/mL [13, 19, 23–25,
28, 38]. Although individual acute-phase reactions proteins
are not satisfactory diagnosis biomarkers, their combined
use with other serum biomarkers may enable more sensitive
and speciﬁc diagnosis (cf., Figure 3). This phenomenon has
recently been termed “host response protein ampliﬁcation
cascade” [122]. Acute-phase proteins could also be directly
produced by the disease tissue.Journal of Biomedicine and Biotechnology 9
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Figure 3: Protein mass spectra collected on CM10 and IMAC-Cu
2+ ProteinChip arrays with serum samples provided by ﬁve patients
with arthritidies (including rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis) and ﬁve noninﬂammatory controls (NIC)
(including osteoarthritis). (a) The inﬂammatory-related proteins S100A8, S100A12, S100A9, and one of its variant S100A9∗ are arthritis
biomarkers detected on CM10 arrays. (b) On IMAC-Cu
2+ ProteinChip arrays, SAA and its 2 variants (SAA-R and SAA-RS) are illustrated,
reproduced from [19].
The moderate speciﬁcity of SELDI-discovered biomark-
ers could be explained by its low sensibility. To date,
SELDI-TOF-MS has not yet identiﬁed any protein marker
present at ng/mL level. This probably indicates that the
lowest detect limit of this technology is around μg/mL as
considered by Diamandis [128]. To overcome this limited
detection sensitivity, the serum (or plasma) proteins can
be fractionated (cf., Section 3.2) before SELDI-TOF-MS
analysis. Fractions could then be loaded on diﬀerent arrays
using complementary binding conditions.
Moreover, the decisive advantage of the mass spectrom-
etry technologies is the capacity to detect protein variants,
protein fragments, and posttranscriptional modiﬁcations
(PTMs), which is usually not possible with aﬃnity-based
technologies. It is now recognized that those components
may be disease-speciﬁc and can be considered as potential
biomarkers (i.e., modiﬁed transthyretin forms in ovarian
cancer in Figure 4 and in familial amyloidotic polyneuropa-
thy) [123, 129, 130].
In the last two years, lots of applications using SELDI-
TOF-MS were published for diagnostic of cancers [25, 42,
44, 131], especially breast [10, 17], prostate [21, 132, 133],
and colorectal cancer [24]. Other recent papers concerning
infectious diseases [22], neurodegenerative disorders [35],
renal diseases [26, 134], and chronic inﬂammatory diseases
[19, 135] also demonstrated the great potential of the
technique.
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Figure 4: Modiﬁed transthyretin forms observed in ovarian cancer
sample, adapted from [123].
SELDI-TOF-MS technology was also used to predict
response to therapy, particularly in cancers. R¨ ocken and
Whelan described in detail the use of SELDI-TOF-MS
to not only predict responses to cancer therapy but also
demonstrateitsinterestinthefollow-upofmetastasisdisease
progression and in the development of drug resistance [44,
136]. Recently platelet factor 4 (PF4) appeared to be a
biomarkerforInﬂiximabnonresponseinCrohn’sdiseaseand
rheumatoid arthritis [29, 137].
Formostofthesestudies,avalidationphaseshouldassess
the validity of the described potential biomarkers against a
larger and more heterogeneous population of patients. The10 Journal of Biomedicine and Biotechnology
robustness of the candidate markers has to be tested against
a level of biological variability that more accurately reﬂects
the variability in the target population.
Unfortunately, several groups failed to validate the
biomarker discovered in their pilot study, such as McLerran
et al. [39, 40], and others [36, 66]. McLerran et al. described
preanalytical bias. They concluded that their ﬁrst study
samples most likely had biases in the sample selection.
Another validation performed by Engwegen et al. using
distinct patient populations conﬁrmed that SAA peak clus-
ters are associated to renal cell carcinoma. However, some
other markers could not be validated [36]. Such examples
demonstrate the importance to strictly control parameters
such as storage, clotting, time of analysis, instrument
performances, sample selection, and statistical classiﬁcation
method.
The urgent need for SOPs in clinical proteomics research
is therefore absolutely mandatory reﬂecting a growing trend
in the ﬁeld [19, 53, 62, 63]. Interaction between researchers,
clinicians, and statisticians is also a key element for the
success.
Altogether, these applications of SELDI-TOF-MS tech-
nology illustrate its capability for discrimination and follow-
up of a multitude of diseases using diﬀerent body ﬂuids
as well as certain therapeutic response prediction. It is
worth mentioning that FDA approved recently the ﬁrst
diagnostictool(namedOVA1)issuedfromSELDIproteomic
researches. It is made of the combination of 5 markers for
ovarian cancer diagnostic.
7. Concluding Remarks
Taking into account herein and previously described recom-
mendations, SELDI-TOF-MS oﬀers very exciting opportuni-
ties to discover not only diagnostic but also prognostic and
mechanistic markers for a number of major diseases.
To face the general criticism, standardized procedures
and recommendations to minimize bias are now followed
by most of the users. However, some challenges still remain,
as for all other proteomic approaches, due in part to the
complexity and the wide dynamic range of the samples.
Sample fractionation and/or enrichment procedure, such as
peptide ligand aﬃnity beads, will certainly be the solution
to visualise the deep proteome. In addition, improvements
in mass spectrometry instrumental performances could be
expected (higher resolution, reducing adduct formation, and
ion suppression), contributing further to more reliable and
faster biomarkers discovery.
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